Journal of Cancer Research and Clinical Oncology

, Volume 113, Issue 6, pp 563–566

Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan)

  • Masanori Sakurai
  • Tetsu Shinkai
  • Kenji Eguchi
  • Yasutsuna Sasaki
  • Tomohide Tamura
  • Kaoru Miura
  • Yasuhiro Fujiwara
  • Atsushi Otsu
  • Noriaki Horiuchi
  • Hidehiko Nakano
  • Kazuhiko Nakagawa
  • Weon-Seon Hong
  • Nagahiro Saijo
Original Papers Clinical Oncology or Epidemiology

DOI: 10.1007/BF00390866

Cite this article as:
Sakurai, M., Shinkai, T., Eguchi, K. et al. J Cancer Res Clin Oncol (1987) 113: 563. doi:10.1007/BF00390866

Summary

A total of 190 patients with unresectable non-small cell lung cancer (NSCLC) were analyzed retrospectively using eight pretreatment and three treatment-related prognostic factors in terms of influence on survival. All the patients received chemotherapy with or without chest irradiation, according to the protocol of phase II or phase III trials of the National Cancer Center Hospital Tokyo between April 1980 and December 1985. The eight pretreatment factors selected were performance status, sex, stage, age, histology, and metastasis to brain, bone or, liver. Three treatment-related factors were radiation therapy to the primary site, response to chemotherapy, and treatment period, before or after clinical adminsitration of cis-diamminedichloroplatinum (II) (CDDP). Of the 190 patients, 71 (37.4%) were alive for more than 1 year, but only 17 patients (8.9%) survived 2 years after the initiation of chemotherapy. By univariate analysis, performance status 0–1, female, no metastasis to bone or liver, response to chemotherapy, and treatment period after CDDP were considered to be favorable prognostic factors. By multiregression analysis, performance status, sex, and treatment period after CDDP proved to be important factors for long-term survival. Consideration of these prognostic factors could enable the results of chemotherapy to be more accurately evaluated, and stratification of patients with advanced NSCLC based on performance status and sex before entry into a randomized controlled trial is recommended.

Key words

Non-small cell lung cancerPrognostic factorsSurvival

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Masanori Sakurai
    • 1
  • Tetsu Shinkai
    • 1
  • Kenji Eguchi
    • 1
  • Yasutsuna Sasaki
    • 1
  • Tomohide Tamura
    • 1
  • Kaoru Miura
    • 1
  • Yasuhiro Fujiwara
    • 1
  • Atsushi Otsu
    • 1
  • Noriaki Horiuchi
    • 1
  • Hidehiko Nakano
    • 1
  • Kazuhiko Nakagawa
    • 1
  • Weon-Seon Hong
    • 2
  • Nagahiro Saijo
    • 1
  1. 1.Department of Internal MedicineNational Cancer Center HospitalTokyoJapan
  2. 2.Department of Internal MedicineKorea Cancer Center HospitalSeoulKorea